Zoledronic Acid is a medicine used to treat high calcium levels in people with certain cancers. It also helps treat bone problems like severe bone loss or bone deformities. It works by slowing down the body's natural process of breaking down bone.
Every report comes from a Lived member, sent anonymously.
Have you tried Zoledronic Acid for Osteoporosis?
Zoledronic acid is a bone-strengthening medicine given as an infusion into a vein. It belongs to a group of drugs called bisphosphonates, which slow the breakdown of bone. In the US it comes as two products that contain the same drug but have different doses and different jobs. Reclast (a 5 mg dose) treats osteoporosis in women after menopause and in men, and can be used to prevent osteoporosis after menopause. It also treats and prevents osteoporosis caused by long-term steroid medicines (glucocorticoids such as prednisone) in people expected to take at least 7.5 mg of prednisone a day, or an equivalent, for a year or more. And it treats Paget's disease of bone, a condition in which bone is broken down and rebuilt in a disorganized way, leaving it enlarged, weaker and sometimes painful. The 4 mg product, first sold under the brand name Zometa and now mostly given as generic zoledronic acid, is used in cancer care. It treats high blood calcium caused by cancer (hypercalcemia of malignancy), and it is given alongside cancer treatment to people with multiple myeloma or with cancer that has spread to the bones. In prostate cancer, it is used once the cancer has progressed despite at least one hormone treatment. Because Reclast and the cancer product are the same drug, someone receiving one should not also be given the other.
Bone is living tissue that is constantly broken down and rebuilt. Cells called osteoclasts dissolve old bone, and other cells lay down new bone in its place. In osteoporosis, breakdown outpaces rebuilding, so bones gradually thin and break more easily. In Paget's disease and in cancers that affect bone, breakdown is excessive and disorganized. Zoledronic acid binds tightly to the mineral in bone, especially where bone is being actively remodeled. When osteoclasts start to break down that bone, they take up the drug, which blocks an enzyme they need to work. Bone breakdown slows, which helps preserve bone strength and lowers the chance of fractures. In cancer-related high calcium, slowing bone breakdown reduces the calcium released into the blood. Because the drug stays attached to bone for a long time, a single infusion keeps acting for many months. That is why one dose a year is enough for osteoporosis, and why one infusion can keep Paget's disease quiet for a long period.
Zoledronic acid is always given by a nurse or doctor as an infusion into a vein, in a clinic, infusion center or hospital. The infusion runs for at least 15 minutes, a minimum set to protect the kidneys. Before every dose, a blood test checks kidney function, and treatment may be postponed if kidney function has dropped or the person is dehydrated. Eating and drinking normally that day, including at least two glasses of water or other fluid in the few hours beforehand, helps protect the kidneys. For osteoporosis, Reclast is given once a year. When it is used to prevent osteoporosis after menopause, it is given once every two years. Paget's disease is usually treated with a single infusion, repeated only if blood tests or symptoms show the disease has become active again. In cancer care, the 4 mg product is usually given every three to four weeks for myeloma or bone metastases, with lower doses for people whose kidneys filter less well. For high blood calcium from cancer, the person is first rehydrated with intravenous fluids, and the infusion can be repeated after at least a week if calcium stays high. Calcium and vitamin D matter with every use. The drug can lower blood calcium, so people are asked to get enough calcium and vitamin D from food or supplements, as the care team advises. After a Reclast infusion for Paget's disease, taking calcium spread through the day is especially important for the next two weeks.
The most common reaction is a short flu-like illness after the infusion: fever, muscle and joint aches and headache. It usually starts within three days and settles within another three, though it occasionally lasts up to two weeks. It is most likely after the first infusion and becomes much less common with later doses. Taking acetaminophen after the infusion can reduce these symptoms; ask the care team whether it suits you. Nausea, vomiting and diarrhea can also occur. Some symptoms call for contacting the care team right away rather than waiting them out. Muscle spasms, twitching or cramps, or numbness and tingling in the fingers, toes or around the mouth, can signal low blood calcium. Severe bone, joint or muscle pain is uncommon but can be disabling, and future doses may be stopped if it happens. New, dull, aching pain in the thigh, hip or groin should also be checked. Bisphosphonates are linked to rare, unusual breaks in the thigh bone that can follow weeks or months of this kind of pain, sometimes with little or no injury. The drug can also rarely cause inflammation in the eye, so new eye symptoms after an infusion are worth reporting.
Zoledronic acid is not given to people with low blood calcium until it has been corrected, or to anyone allergic to it. Reclast is not used when kidney function is severely reduced (a creatinine clearance, an estimate of how well the kidneys filter blood, below 35 mL/min) or when there is sudden kidney injury. Tell the care team about any kidney problems, past thyroid or parathyroid surgery, conditions or surgery that reduce how well the gut absorbs nutrients, and asthma triggered by aspirin, since bisphosphonates can rarely tighten the airways in people with that sensitivity. Some medicines add to the risk of kidney injury or low calcium. These include diuretics (water pills), especially the loop diuretic type; a group of antibiotics called aminoglycosides; and NSAIDs (nonsteroidal anti-inflammatory pain relievers such as ibuprofen), which can strain the kidneys. The prescriber should know about every prescription and over-the-counter medicine. Osteonecrosis of the jaw is a rare but serious problem in which an area of jawbone dies and does not heal. Most cases have been in people with cancer receiving intravenous bisphosphonates, often after dental procedures such as tooth extraction, and the risk may grow with longer use. The prescriber examines the mouth before treatment starts, and a dental checkup first is sensible, especially for people with cancer or existing dental problems. Good daily dental care and regular checkups help. Planned dental surgery should be discussed with both the dentist and the prescriber, and jaw pain or a sore in the mouth that does not heal should be reported right away. Zoledronic acid should not be used during pregnancy or while breastfeeding. Because it is stored in bone and released slowly for years, there is a potential risk to a baby even when pregnancy happens after treatment ends, so anyone who could become pregnant should discuss this before starting.
People can usually go about their day after an infusion. If the flu-like reaction comes, it tends to appear over the following day or two and fade within a few days. For osteoporosis, people do not feel the drug working. Its benefit is fewer fractures over time. In the main trial of women aged 65 to 89 with osteoporosis, three yearly infusions cut the share who had a new spine fracture over three years from about 11% to about 3%, and hip fractures from 2.5% to 1.4%. Fewer spine fractures were already seen in the first year. The best length of treatment is not known. Because the drug stays in bone, people at lower fracture risk may be offered a break after three to five years, with their fracture risk rechecked periodically, while the decision for others depends on how high their risk remains. For Paget's disease, a single infusion often keeps the disease quiet for a long time. Blood tests of alkaline phosphatase, an enzyme that rises when bone turnover is high, show whether it has become active again. In cancer care, the aim is to prevent bone complications such as fractures, spinal cord compression and the need for radiation or surgery to bone. In a trial in prostate cancer that had spread to bone, 33% of people on zoledronic acid had such a complication, compared with 44% on placebo. Doses continue alongside cancer treatment, with a kidney check before each one.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Zoledronic Acid, what you've noticed, or ask the community a question.